Genome Medicine (Feb 2024)

Implementation of type 1 diabetes genetic risk screening in children in diverse communities: the Virginia PrIMeD project

  • Kristin A. Guertin,
  • David R. Repaske,
  • Julia F. Taylor,
  • Eli S. Williams,
  • Suna Onengut-Gumuscu,
  • Wei-Min Chen,
  • Sarah R. Boggs,
  • Liping Yu,
  • Luke Allen,
  • Lacey Botteon,
  • Louis Daniel,
  • Katherine G. Keating,
  • Mika K. Labergerie,
  • Tyler S. Lienhart,
  • Jorge A. Gonzalez-Mejia,
  • Matt J. Starnowski,
  • Stephen S. Rich

DOI
https://doi.org/10.1186/s13073-024-01305-8
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Population screening for risk of type 1 diabetes (T1D) has been proposed to identify those with islet autoimmunity (presence of islet autoantibodies). As islet autoantibodies can be transient, screening with a genetic risk score has been proposed as an entry into autoantibody testing. Methods Children were recruited from eight general pediatric and specialty clinics across Virginia with diverse community settings. Recruiters in each clinic obtained informed consent/assent, a medical history, and a saliva sample for DNA extraction in children with and without a history of T1D. A custom genotyping panel was used to define T1D genetic risk based upon associated SNPs in European- and African-genetic ancestry. Subjects at “high genetic risk” were offered a separate blood collection for screening four islet autoantibodies. A follow-up contact (email, mail, and telephone) in one half of the participants determined interest and occurrence of subsequent T1D. Results A total of 3818 children aged 2–16 years were recruited, with 14.2% (n = 542) having a “high genetic risk.” Of children with “high genetic risk” and without pre-existing T1D (n = 494), 7.0% (34/494) consented for autoantibody screening; 82.4% (28/34) who consented also completed the blood collection, and 7.1% (2/28) of them tested positive for multiple autoantibodies. Among children with pre-existing T1D (n = 91), 52% (n = 48) had a “high genetic risk.” In the sample of children with existing T1D, there was no relationship between genetic risk and age at T1D onset. A major factor in obtaining islet autoantibody testing was concern over SARS-CoV-2 exposure. Conclusions Minimally invasive saliva sampling implemented using a genetic risk score can identify children at genetic risk of T1D. Consent for autoantibody screening, however, was limited largely due to the SARS-CoV-2 pandemic and need for blood collection.

Keywords